FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2942413717> ?p ?o ?g. }

• W2942413717 endingPage "1350" @default.
• W2942413717 startingPage "1341" @default.
• W2942413717 abstract "Adenomyosis is a benign uterine disease where endometrial glands and stroma are found within the myometrium surrounded by an area of hypertrophic myometrium. Symptomatology includes heavy menstrual bleeding and pelvic pain. The pathogenesis of adenomyosis is not known; however, animal models have shown increased uterine concentration of prolactin as a risk factor. Prolactin acts as a smooth muscle cell mitogen. If prolactin is central to adenomyosis pathogenesis, reducing uterine prolactin could be a possible medical treatment option. In this pilot study, we aim to evaluate the effect of bromocriptine, a prolactin inhibitor, on menstrual bleeding and pain in women with adenomyosis.23 women with diffuse adenomyosis were enrolled from a university hospital in Sweden and a tertiary care center in the USA. Nineteen patients completed 6 months of treatment with vaginal bromocriptine at a dose of 5 mg daily. Participants completed validated measures at baseline, 3 and 6 months of treatment, and at 9 months (3 months after cessation of bromocriptine). Validated measures utilized included Pictorial Blood Loss Assessment Chart (PBLAC), Aberdeen Menorrhagia Clinical Outcomes Questionnaire (AMCOQ), Visual Analog Scale for pain (VAS), McGill Pain Questionnaire (MPQ), Endometriosis Health Profile (EHP-30), Female Sexual Function Index (FSFI) and the Fibroid Symptom Quality of Life (UFS-QOL) symptom severity and health-related quality of life (HRQL) subscores. Scores were compared between baseline and 9 months using the Wilcoxon signed rank test.Mean age of participants was 44.8 years. About 77.8% reported PBLAC scores >250 and 68.4% reported moderate to severe pain at baseline. Compared with baseline, women had lower 9-month scores (median [interquartile range] for all) on PBLAC (baseline 349 [292-645] vs 9-month 233 [149-515], P = 0.003), VAS (5.0 [4-8.3] vs 2.5 [0-4.5], P < 0.001), EHP Core Pain (15.9 [9.1-50.0] vs 3.4 [2.3-34.1], P = 0.029), EHP Core Self-image (41.7 [16.7-58.3] vs 25 [0-5], P = 0.048) and Symptom Severity Score (60 [44-72] vs 44 [25-56], P < 0.001) and higher HRQL scores (57 [37-63] vs 72 [51-85], P < 0.001) following bromocriptine treatment. Other EHP core parameters and FSFI were not significantly different.Significant improvement in menstrual bleeding, pain and quality of life after vaginal bromocriptine treatment suggests a novel therapeutic agent for adenomyosis." @default.
• W2942413717 created "2019-05-03" @default.
• W2942413717 creator A5005951877 @default.
• W2942413717 creator A5009592023 @default.
• W2942413717 creator A5010282758 @default.
• W2942413717 creator A5021933390 @default.
• W2942413717 creator A5044570765 @default.
• W2942413717 creator A5075006014 @default.
• W2942413717 date "2019-06-14" @default.
• W2942413717 modified "2023-10-17" @default.
• W2942413717 title "Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: A pilot study" @default.
• W2942413717 cites W1570978040 @default.
• W2942413717 cites W1587113429 @default.
• W2942413717 cites W1813963939 @default.
• W2942413717 cites W1957937187 @default.
• W2942413717 cites W1966951938 @default.
• W2942413717 cites W1967036278 @default.
• W2942413717 cites W1993062940 @default.
• W2942413717 cites W2016594241 @default.
• W2942413717 cites W2022534203 @default.
• W2942413717 cites W2028056243 @default.
• W2942413717 cites W2030038376 @default.
• W2942413717 cites W2035655054 @default.
• W2942413717 cites W2042374015 @default.
• W2942413717 cites W2060544491 @default.
• W2942413717 cites W2067826519 @default.
• W2942413717 cites W2071457523 @default.
• W2942413717 cites W2074501002 @default.
• W2942413717 cites W2112997260 @default.
• W2942413717 cites W2135057319 @default.
• W2942413717 cites W2145496499 @default.
• W2942413717 cites W2154062513 @default.
• W2942413717 cites W2314165178 @default.
• W2942413717 cites W2415396582 @default.
• W2942413717 cites W2499161072 @default.
• W2942413717 cites W4235220721 @default.
• W2942413717 cites W4251001509 @default.
• W2942413717 doi "https://doi.org/10.1111/aogs.13632" @default.
• W2942413717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31025313" @default.
• W2942413717 hasPublicationYear "2019" @default.
• W2942413717 type Work @default.
• W2942413717 sameAs 2942413717 @default.
• W2942413717 citedByCount "28" @default.
• W2942413717 countsByYear W29424137172020 @default.
• W2942413717 countsByYear W29424137172021 @default.
• W2942413717 countsByYear W29424137172022 @default.
• W2942413717 countsByYear W29424137172023 @default.
• W2942413717 crossrefType "journal-article" @default.
• W2942413717 hasAuthorship W2942413717A5005951877 @default.
• W2942413717 hasAuthorship W2942413717A5009592023 @default.
• W2942413717 hasAuthorship W2942413717A5010282758 @default.
• W2942413717 hasAuthorship W2942413717A5021933390 @default.
• W2942413717 hasAuthorship W2942413717A5044570765 @default.
• W2942413717 hasAuthorship W2942413717A5075006014 @default.
• W2942413717 hasBestOaLocation W29424137171 @default.
• W2942413717 hasConcept C126322002 @default.
• W2942413717 hasConcept C131872663 @default.
• W2942413717 hasConcept C141071460 @default.
• W2942413717 hasConcept C14184104 @default.
• W2942413717 hasConcept C159110408 @default.
• W2942413717 hasConcept C1862650 @default.
• W2942413717 hasConcept C2779064019 @default.
• W2942413717 hasConcept C2779166600 @default.
• W2942413717 hasConcept C2779522080 @default.
• W2942413717 hasConcept C2779951463 @default.
• W2942413717 hasConcept C2780136519 @default.
• W2942413717 hasConcept C29456083 @default.
• W2942413717 hasConcept C71315377 @default.
• W2942413717 hasConcept C71924100 @default.
• W2942413717 hasConceptScore W2942413717C126322002 @default.
• W2942413717 hasConceptScore W2942413717C131872663 @default.
• W2942413717 hasConceptScore W2942413717C141071460 @default.
• W2942413717 hasConceptScore W2942413717C14184104 @default.
• W2942413717 hasConceptScore W2942413717C159110408 @default.
• W2942413717 hasConceptScore W2942413717C1862650 @default.
• W2942413717 hasConceptScore W2942413717C2779064019 @default.
• W2942413717 hasConceptScore W2942413717C2779166600 @default.
• W2942413717 hasConceptScore W2942413717C2779522080 @default.
• W2942413717 hasConceptScore W2942413717C2779951463 @default.
• W2942413717 hasConceptScore W2942413717C2780136519 @default.
• W2942413717 hasConceptScore W2942413717C29456083 @default.
• W2942413717 hasConceptScore W2942413717C71315377 @default.
• W2942413717 hasConceptScore W2942413717C71924100 @default.
• W2942413717 hasFunder F4320306143 @default.
• W2942413717 hasFunder F4320322315 @default.
• W2942413717 hasIssue "10" @default.
• W2942413717 hasLocation W29424137171 @default.
• W2942413717 hasLocation W29424137172 @default.
• W2942413717 hasOpenAccess W2942413717 @default.
• W2942413717 hasPrimaryLocation W29424137171 @default.
• W2942413717 hasRelatedWork W2074845402 @default.
• W2942413717 hasRelatedWork W2101649583 @default.
• W2942413717 hasRelatedWork W2225920452 @default.
• W2942413717 hasRelatedWork W3012473392 @default.
• W2942413717 hasRelatedWork W3035080994 @default.
• W2942413717 hasRelatedWork W3093077826 @default.
• W2942413717 hasRelatedWork W4221124180 @default.
• W2942413717 hasRelatedWork W4226486958 @default.

• next